On 14 October 2016, orphan designation (EU/3/16/1756) was granted by the European Commission to Kyowa Kirin Limited, United Kingdom, for mogamulizumab for the treatment of cutaneous T-cell lymphoma.
The sponsorship was transferred to Kyowa Kirin Holdings B.V., The Netherlands, in August 2018.
Mogamulizumab has been authorised in the EU as Poteligeo since 22 November 2018.
|Disease / condition||
Treatment of cutaneous T-cell lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.